ArticleMedicine2026
Focus on CCL19: A Mendelian randomization study on genetic evidence of immune cells influencing osteoarthritis severity via inflammatory proteins.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Osteoarthritis (OA) is a prevalent degenerative joint disorder whose pathogenesis involves immune-inflammatory regulation. Immune cells may influence OA progression by modulating inflammatory proteins; however, the underlying mechanisms remain inadequately understood. This study used Mendelian randomization (MR) analysis to investigate the causal effects of immune cells on OA. Additionally, it evaluated the mediating role of inflammatory proteins, particularly chemokine (C-C motif) ligand 19 (CCL19). Public genome-wide association study datasets were utilized, encompassing genetic data for 471 immune cell types, 91 inflammatory proteins, and OA (including generalized OA, knee osteoarthritis (KOA), and KOA with surgery). A bidirectional bivariate MR approach was employed to assess causal relationships between immune cells and OA; while mediating MR quantified the mediating effects of inflammatory proteins. Instrument selection criteria were P < 5 × 10-8 and F > 10. The inverse variance weighted (IVW) method was the primary analytic technique, further validated through MR-Egger regression for robustness. MR analysis revealed that myeloid cell activation (e.g., CD33+ monocytes) positively correlated with OA risk (odds ratio [OR] = 1.014-1.049, P < .05), whereas regulatory T cell expression (e.g., CD4 on CD39+ activated Tregs) negatively correlated with risk (OR = 0.921-0.958, P < .05). The inflammatory protein CCL19 exhibited a protective effect against OA (OR = 0.876-0.924, P < .001), yet mediated an enhanced risk effect of immune cells on OA. Mediation analysis identified 5 significant pathways (P < .05), with mediation proportions ranging from -13..5 to 20.5%, all showing CCL19 as a positive risk mediator. The findings suggest that immune cells influence the progression of OA through the mediation of CCL19, underscoring the critical role of the immune-inflammatory axis in the pathogenesis of OA. CCL19 may represent a promising therapeutic target, paving the way for the development of therapies aimed at inflammation modulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.